Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in this application.

Listing of Claims:

1. **(currently amended)** A compound represented by formula I-1:



I-1

and the pharmaceutically acceptable salts and esters thereof wherein:

"a" is an integer selected from 1, 2 and 3; and b and c are each integers independently selected from 0, 1 and 2;

"A" represents a methylene or ethylene group;

each R^{1a} is independently selected from the group consisting of: -H, -F, -Cl, -Br, $-C_{1-6}$alkyl, -CN, -OH, $-OC_{1-6}$ alkyl, -fluoroC_{1-6} alkyl, -fluoroC_{1-6} alkoxy, $-N(R^a)_2$, $-C_{1-6}$ alkyl$N(R^a)_2$, $-NHC(O)C_{1-4}$alkyl, $-C(O)NHC_{1-4}$alkyl and $-C(O)N(C_{1-4}alkyl)_2$;

each R^{1b} is independently selected from the group consisting of: -H, -F, $-C_{1-6}$ alkyl, -OH, $-OC_{1-6}$ alkyl, -fluoroC_{1-6}alkyl, -fluoroC_{1-6}alkoxy, $-N(R^a)_2$and $-C_{1-6}$alkyl$N(R^a)$, or one R^{1b} group can represent oxo and the other is as previously defined;

R^1 represents -H or is selected from the group consisting of:

a) halo, -OH, $-CO_2R^a$, $-C(O)NR^aR^b$, $-N(R^a)_2$, $-S(O)_2NR^aR^b$, $-NO_2$, $-SO_2NR^bC(O)R^a$, $-NR^bSO_2R^a$, $-NR^bC(O)R^a$, $-C(O)SO_2NR^aR^b$, $-NR^bC(O)NR^aR^b$, $-NR^bCO_2R^a$, $-OC(O)NR^aR^b$, $-C(O)NR^bNR^aR^b$, -CN, $-S(O)_pR^a$ and $-OSO_2R^a$,

b) $-C_{1-10}$alkyl, $-C_{2-10}$alkenyl, $-C_{2-10}$alkynyl, $-OC_{1-10}$alkyl, $-OC_{3-10}$alkenyl and $-OC_{3-10}$alkynyl, said groups being optionally substituted with: -OH, $-CO_2R^a$, $-C(O)NR^aR^b$, $-C(O)N(R^a)C_{1-6}$alkenyl, $-C(O)N(R^a)C_{1-6}$alkynyl, $-N(R^a)_2$, $-S(O)_2NR^aR^b$, $-SO_2NR^bC(O)R^a$, $-NR^bSO_2R^a$, $-NR^bC(O)R^a$, $-C(O)SO_2NR^aR^b$, $-NR^bC(O)NR^aR^b$, $-NR^bCO_2R^a$, $-OC(O)NR^aR^b$, $-C(O)NR^bNR^aR^b$, $-S(O)_pR^a$, Aryl, and up to 5 fluoro groups;

c) Aryl optionally substituted with 1-2 members selected from the group consisting of: -F, -Cl, -Br, -C_{1-6} alkyl, -C_{3-6}cycloalkyl, -CN, -OH, -OC_{1-6} alkyl, -fluoroC_{1-6} alkyl, -fluoroC_{1-6}alkoxy, -NH_2, -NHC_{1-4}alkyl, -$N(C_{1-4}alkyl)_2$, -C_{1-6}alkylNH_2, -C_{1-6}alkyl-NHC_{1-4}alkyl, -C_{1-6}alkyl$N(C_{1-4}alkyl)_2$, -C_{1-6}alkyl-CN, -$NHC(O)C_{1-4}$alkyl, -$C(O)NHC_{1-4}$alkyl and -$C(O)N(C_{1-4}alkyl)_2$;

each p independently represents an integer selected from 0, 1 and 2;

;

R^4 and R^5 are each independently selected from the group consisting of -H, -C_{1-6} alkyl, -OC_{1-6}alkyl, -OH, -fluoro, -fluoroC_{1-6}alkyl, -fluoroC_{1-6}alkoxy, -$N(R^a)_2$, and

CR^4R^5 can represent a group selected from carbonyl, thiocarbonyl, $C{=}NR^a$ and a 3-7 membered cycloalkyl ring,

Y is quinolinyl;

each R^a is independently selected from the group consisting of –H and :

(a) -C_{1-10}alkyl, -C_{3-6}cycloalkyl, -C_{3-10}alkenyl, or –C_{3-10}alkynyl, optionally substituted with 1-3 fluoro groups or 1-2 members selected from the group consisting of: -OH, -OC_{1-6}alkyl, -CN, -NH_2, -NHC_{1-4}alkyl, and -$N(C_{1-4}alkyl)_2$;

(b) Aryl or Ar-C_{1-6}alkyl-, the aryl portions being optionally substituted with 1-2 of -C_{1-6} alkyl, -CN, -OH, -OC_{1-6} alkyl, -fluoroC_{1-6} alkyl, -fluoroC_{1-6} alkoxy, -C_{1-6}alkylNH_2, -C_{1-6}alkylNHC_{1-4}alkyl, -C_{1-6}alkyl$N(C_{1-4}alkyl)_2$, -NH_2, -NHC_{1-4}alkyl, -$N(C_{1-4}alkyl)_2$, -$NHC(O)C_{1-4}$alkyl, -$C(O)NHC_{1-4}$alkyl, -$C(O)N(C_{1-4}alkyl)_2$, -CO_2H and -CO_2C_{1-6}alkyl groups, and 1-3 -F, -Cl or -Br groups;

and the alkyl portion of Ar-C_{1-6}alkyl- being optionally substituted with –OH, -OC_{1-6}alkyl, -NH_2, -NHC_{1-4}alkyl, -$N(C_{1-4}alkyl)_2$, and 1-3 fluoro groups;

each R^b is independently selected from the group consisting of: -H, -NH_2, and -C_{1-10}alkyl optionally substituted with members selected from the group consisting of 1-3 fluoro groups and 1-2 of -OH, -OC_{1-6}alkyl, -NH_2, -NHC_{1-4}alkyl and -$N(C_{1-4}alkyl)_2$;

and when present in the same moiety, (a) R^a and R^b, (b) two R^a groups or (c) two R^b groups can be taken in combination with the atom or atoms to which they are attached and any intervening atoms and represent a 4-7 membered ring containing 0-3 heteroatoms selected from O, $S(O)_p$ and N, and the 4-7 membered ring may be optionally substituted with a member selected from the group consisting of -C_{1-6}alkyl, -C_{2-6}acyl and oxo.

2. **(currently amended)** The compound of claim 1 of structural formula Ia-1:



Ia-1

and the pharmaceutically acceptable salts and esters thereof, wherein "a" is an integer selected from 1, 2 and 3; and b and c are each integers independently selected from 0, 1 and 2; provided that the sum of "a" + b + c is from 1 to 5.

3. **(canceled)**

4. **(currently amended)** The compound of claim 1 of structural formula Ib-1:



Ib-1

and the pharmaceutically acceptable salts and esters thereof wherein: "a" is an integer selected from 2 and 3; and b and c are integers independently selected from 0 and 1; provided that the sum of "a" + b + c is from 2 to 4.

5. **(original)** The compound of claim 4 wherein "a" is 2, and b and c are integers selected from 0 and 1.

6. **(canceled)**

7. **(currently amended)** The compound of claim 1 wherein of the three R^{1a} groups shown in the generic structural drawing of formula I-1, two R^{1a} groups represent -H and one R^{1a} group is selected from the group consisting of: -F, -Cl, -C_{1-6} alkyl, -CN, -OC_{1-6} alkyl, -fluoroC_{1-6} alkyl, -fluoroC_{1-6}alkoxy, -$N(R^a)_2$, -C_{1-6}alkyl$N(R^a)_2$, -$NHC(O)C_{1-4}$alkyl, -$C(O)NHC_{1-4}$alkyl and -$C(O)N(C_{1-4}alkyl)_2$.

8. **(canceled)**

9. **(previously presented)** The compound of claim 1 wherein both R^{1b} groups represent -H.

10. **(currently amended)** The compound of claim 1 wherein R^1 represents a member selected from the group consisting of:

a) -$C(O)NR^aR^b$, -$N(R^a)_2$, -$S(O)_2NR^aR^b$, -$SO_2NR^bC(O)R^a$, -$NR^bSO_2R^a$, -$NR^bC(O)R^a$, -CN, -$S(O)_pR^a$ and -OSO_2R^a; and

b) -C_{1-10}alkyl, -C_{3-6}alkenyl, -C_{3-6}alkynyl, -OC_{1-10}alkyl, -OC_{3-6}alkenyl and -OC_{3-10}alkynyl, said groups being optionally substituted with a member selected form the group consisting of: -CO_2R^a, -$C(O)NR^aR^b$, -$C(O)N(R^a)C_{1-6}$alkenyl, -$C(O)N(R^a)C_{1-6}$alkynyl, -$N(R^a)_2$, -$S(O)_2NR^aR^b$, -$SO_2NR^bC(O)R^a$, -$NR^bSO_2R^a$, $NR^bC(O)R^a$, -$S(O)_pR^a$, Aryl, and up to 5 fluoro groups.

11 - 13. **(canceled)**

14. **(currently amended)** The compound of claim 1 wherein -(CR^4R^5)- represents -CH_2-.

15 - 20. **(canceled)**

21. **(currently amended)** The compound of claim 1 of structural formula Ic-1:



Ic-1

wherein R^4 and R^5 are both –H;



R^1 is selected from the group consisting of:

a) -OC(O)NR^{a}R^b, and -C(O)NR^{a}R^b; and
b) C_{1-3}alkyl substituted with a member selected from: –C(O)-NR^{a}R^b.

22 - 23. **(canceled)**

24. **(original)** A pharmaceutical composition comprised of a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

25. **(canceled)**

26. **(withdrawn)** A method for treating a leukotriene-mediated medical condition comprising administering a therapeutically effective amount of a compound of claim 1 to a patient in need of such treatment.

27. **(canceled)**

28. **(withdrawn)** The method of Claim 26 wherein said leukotriene-mediated medical condition is atherosclerosis.

29 - 31. **(canceled)**

32. **(withdrawn)** A method of preventing or reducing the risk for a leukotriene-mediated medical condition comprising administering a prophylactically effective amount of a compound of claim 1 to a patient in need of such treatment.

33. **(canceled)**

34. **(withdrawn)** The method of Claim 32 wherein said leukotriene-mediated medical condition is an atherosclerotic disease event.

35. **(withdrawn)** The method of treating atherosclerosis of claim 28 further comprising administering to the patient a compound selected from the group consisting of an HMG-CoA reductase inhibitor, cholesterol absorption inhibitor, CETP inhibitor, PPARγ agonist, PPARα agonist, PPAR dual α/γ agonist, and combinations thereof.

36. **(withdrawn)** The method of Claim 26 wherein said leukotriene-mediated medical condition is selected from asthma, allergies, allergic conditins and COPD.